维升药业那韦培肽完成中国2期临床试验,用于治疗软骨发育不全

时代财经
12 May

本文来源:时代财经5月12日,维升药业(02561.HK)宣布其在研的用于治疗软骨发育不全(Achondroplasia, ACH)的那韦培肽(Navepegritide, TransCon CNP)中国 2 期临床试验已全部顺利完成(包括52周双盲治疗期以及52周开放标签扩展阶段),并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据维升药业介绍,那韦培肽中国2期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10